Fortress’ business model, through its subsidiaries and partner companies, takes advantage of inefficiencies in life sciences to license and develop clinical stage medicines. Fortress creates long-term value through royalties from sales and equity dividends while avoiding large research and development expenses. This model incentivizes the team to continue to expand Fortress’ pipeline of clinical medicines while continuously adding value to its existing subsidiaries and partner companies.
Get in Touch
For questions regarding our company, drug candidates, marketed products, business development opportunities, or for general inquiries, please reach out to us.Ask a Question